Editorial
Split Viewer
Korean J Hematol 2010; 45(4):
Published online December 31, 2010
https://doi.org/10.5045/kjh.2010.45.4.215
© The Korean Society of Hematology
Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) activation in acquired hemostatic dysfunction: a diagnostic challenge
Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
REFERENCES
- Bajzar, L, Manuel, R, Nesheim, ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem, 1995;270;14477-14484.
- Boffa, MB, Koschinsky, ML. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem, 2007;40;431-442.
- Toh, CH. Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction. Blood Coagul Fibrinolysis, 2003;14;S69-S71.
- Redlitz, A, Nicolini, FA, Malycky, JL, Topol, EJ, Plow, EF. Inducible carboxypeptidase activity. A role in clot lysis in vivo. Circulation, 1996;93;1328-1330.
- Heylen, E, Miljic, P, Willemse, J, et al. Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia. Thromb Res, 2009;124;427-432.
- Kraft, P, Schwarz, T, Meijers, JC, Stoll, G, Kleinschnitz, C. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke. PLoS One, 2010;5;e11658.
- Renckens, R, Roelofs, JJ, ter Horst, SA, et al. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J Immunol, 2005;175;6764-6771.
- Ceresa, E, Brouwers, E, Peeters, M, Jern, C, Declerck, PJ, Gils, A. Development of ELISAs measuring the extent of TAFI activation. Arterioscler Thromb Vasc Biol, 2006;26;423-428.
- Park, R, Song, J, An, SS. Elevated TAFIa/ai levels in patient with sepsis and normal controls with TAFIa/ai specific ELISA. Korean J Hematol, 2010;45;264-268.
- Emonts, M, de Bruijne, EL, Guimarães, AH, et al. Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. J Thromb Haemost, 2008;6;268-276.
PDF
Standard view
Export citation
Share Article
Editorial
Korean J Hematol 2010; 45(4): 215-216
Published online December 31, 2010 https://doi.org/10.5045/kjh.2010.45.4.215
Copyright © The Korean Society of Hematology.
Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) activation in acquired hemostatic dysfunction: a diagnostic challenge
Hyun Kyung Kim, M.D.
Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
- Bajzar, L, Manuel, R, Nesheim, ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem, 1995;270;14477-14484.
- Boffa, MB, Koschinsky, ML. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem, 2007;40;431-442.
- Toh, CH. Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction. Blood Coagul Fibrinolysis, 2003;14;S69-S71.
- Redlitz, A, Nicolini, FA, Malycky, JL, Topol, EJ, Plow, EF. Inducible carboxypeptidase activity. A role in clot lysis in vivo. Circulation, 1996;93;1328-1330.
- Heylen, E, Miljic, P, Willemse, J, et al. Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia. Thromb Res, 2009;124;427-432.
- Kraft, P, Schwarz, T, Meijers, JC, Stoll, G, Kleinschnitz, C. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke. PLoS One, 2010;5;e11658.
- Renckens, R, Roelofs, JJ, ter Horst, SA, et al. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J Immunol, 2005;175;6764-6771.
- Ceresa, E, Brouwers, E, Peeters, M, Jern, C, Declerck, PJ, Gils, A. Development of ELISAs measuring the extent of TAFI activation. Arterioscler Thromb Vasc Biol, 2006;26;423-428.
- Park, R, Song, J, An, SS. Elevated TAFIa/ai levels in patient with sepsis and normal controls with TAFIa/ai specific ELISA. Korean J Hematol, 2010;45;264-268.
- Emonts, M, de Bruijne, EL, Guimarães, AH, et al. Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. J Thromb Haemost, 2008;6;268-276.
Previous Article
